Latest News and Press Releases
Want to stay updated on the latest news?
-
VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class...
-
Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic tetraplegia.Primary endpoint will be the change from baseline in GRASSP...
-
New York, USA, April 02, 2026 (GLOBE NEWSWIRE) -- The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight The SCI treatment pipeline continues to expand,...
-
Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026....
-
Los Angeles, CA, March 05, 2026 (GLOBE NEWSWIRE) -- ANEUVO, a medical technology company advancing non-invasive neuromodulation for people living with spinal cord injury, today announced the closing...
-
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
-
VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
-
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
-
Los Angeles, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- ANEUVO (Niche Biomedical, Inc. d.b.a. ANEUVO), a medical technology company advancing non-invasive neuromodulation for people living with spinal...
-
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium